首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Preemptive Treatment of Minimal Residual Disease (MRD) with IL-15-Activated Cytokine-Induced Killer Cells for the Prevention of Relapse in Leukemia Patients after Allogeneic Stem Cell Transplantation - Results of a Pilot Study

【24h】

Preemptive Treatment of Minimal Residual Disease (MRD) with IL-15-Activated Cytokine-Induced Killer Cells for the Prevention of Relapse in Leukemia Patients after Allogeneic Stem Cell Transplantation - Results of a Pilot Study

机译：IL-15激活的细胞因子诱导的杀伤细胞对微小残留病（MRD）的抢先治疗，以预防异基因干细胞移植后白血病患者的复发-一项初步研究的结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation》 |2016年第1期|共1页
作者
Bader Peter; Huenecke Sabine; Boenig Halyard; Merker Michael; Jarisch Andrea; Soerensen Jan; Willasch Andre; Bug Gesine; Schulz Ansgar; Klingebiel Thomas E.; Rettinger Eva;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类治疗学;
关键词

相似文献

外文文献
中文文献
专利

1. Preemptive Treatment of Minimal Residual Disease (MRD) with IL-15-Activated Cytokine-Induced Killer Cells for the Prevention of Relapse in Leukemia Patients after Allogeneic Stem Cell Transplantation - Results of a Pilot Study [J] . Bader Peter, Huenecke Sabine, Boenig Halyard, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2016,第3Suppla1期

机译：IL-15激活的细胞因子诱导的杀伤细胞对微小残留病（MRD）的抢先治疗，以预防异基因干细胞移植后白血病患者的复发-一项初步研究的结果
2. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes. [J] . Kroger N, Bacher U, Bader P, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2010,第9期

机译：NCI首届异基因造血干细胞移植后复发的生物学，预防和治疗国际研讨会：疾病特异性方法和策略委员会的报告，用于监测异基因干细胞移植后的复发。第一部分：方法，急性白血病和骨髓增生异常综合症。
3. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies. [J] . Kroger N, Bacher U, Bader P, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2010,第10期

机译：NCI第一次国际研讨会，关于异基因造血干细胞移植后复发的生物学，预防和治疗：来自疾病特异性方法和策略委员会的报告，用于监测异基因干细胞移植后的复发。第二部分：慢性白血病，骨髓增生性肿瘤和淋巴样恶性肿瘤。
4. Detection of Minimal Residual Disease (MRD) in Patients with Leukemia Using Microfluidic-Based Analysis [C] . Rolf Muller, Bryan Green, Matt Hupert, International Molecular Medicine Tri-Conference. . 2016

机译：使用基于微流体分析的白血病患者最小残留疾病（MRD）的检测
5. Folate status and risk of relapse following allogeneic hematopoietic cell transplant for chronic myelogenous leukemia. [D] . Robien, Kimberly Ziemer. 2003

机译：异基因造血细胞移植治疗慢性粒细胞白血病后的叶酸状况和复发风险。
6. Molecular Detection of Minimal Residual Disease before Allogeneic Stem Cell Transplantation Predicts a High Incidence of Early Relapse in Adult Patients with NPM1 Positive Acute Myeloid Leukemia [O] . Federico Lussana, Chiara Caprioli, Paola Stefanoni, 2019

机译：同种异体干细胞移植之前最小残留疾病的分子检测可预测NPM1阳性急性髓细胞性白血病成年患者早期复发的高发生率
7. Allogeneic Hematopoietic Cell Transplantation (HCT) Yields Lower Relapse Rates but No Overall Survival Benefit for Adults with Acute Lymphoblastic Leukemia (ALL) in First Minimal Residual Disease (MRD)-Negative Remission [O] . Cassaday Ryan D., Potts D. Alan, Stevenson Philip A., 2015

机译：同种异体造血细胞移植（HCT）可使复发率降低，但对于首发最小残留病（MRD）-阴性缓解的急性淋巴细胞白血病（ALL）的成年人没有总体生存益处

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号